2024-09-06 - Analysis Report
##  MRK Stock Analysis Report

This report analyzes the performance of **Merck & Co., Inc. (MRK)**, a global healthcare company that discovers, develops, manufactures, and markets a broad range of prescription medicines, vaccines, biological therapies, and animal health products.

### Performance Analysis

**1.  Performance vs. S&P 500 (VOO)**

*   MRK's cumulative return is **52.93%**, while the S&P 500's cumulative return is **89.66%**.
*   This represents a difference of **-36.73%** compared to the S&P 500.
*   The relative divergence, which measures MRK's performance against the S&P 500's historical range, currently stands at **38.25%**. This indicates that MRK's performance is currently in the lower 38.25% percentile of its historical performance range relative to the S&P 500.

**2.  Recent Price Movement**

*   Current Closing Price: **$118.45**
*   5-Day Moving Average: **$117.22**
*   20-Day Moving Average: **$114.88**
*   60-Day Moving Average: **$122.73**

The price is currently above the 5-day and 20-day moving averages, suggesting short-term bullish momentum. However, the price is below the 60-day moving average, suggesting potential for a long-term pullback.

**3. Technical Indicators**

*   RSI: **81.9** (Overbought territory)
*   PPO: **0.74** (Strong bullish momentum)
*   Delta_Previous_Relative_Divergence: **-6.71** (Indicates short-term bearish trend)
*   Expected_Return: **11.87%** (Represents the maximum estimated return over a 5-year period based on current investment)

The RSI suggests that the stock is overbought and may be due for a correction. The PPO indicates strong bullish momentum, but the negative delta_previous_relative_divergence suggests a potential short-term decline.

**4. Recent Earnings and Outlook**

| Date       | EPS  | Revenue      |
| ---------- | ---- | ------------- |
| 2024-08-05 | 2.15 | $16.11 B      |
| 2024-05-03 | 1.88 | $15.78 B      |
| 2023-11-03 | 1.87 | $15.96 B      |
| 2023-08-07 | -2.35 | $15.04 B      |
| 2024-08-05 | -2.35 | $15.04 B      |

The latest earnings report for the quarter ended August 5th, 2024, showed an EPS of $2.15, surpassing analyst expectations. Revenue also came in above estimates, indicating strong performance. However, the company's past earnings have been volatile, with significant declines in 2023.

**5. Overall Analysis**

MRK's stock price has underperformed the S&P 500 in the long term. However, recent earnings have been strong, and technical indicators suggest potential for short-term growth. While the RSI suggests potential for a correction, the strong PPO and positive expected return indicate potential for continued growth. It is important to monitor the stock closely, particularly given the recent volatility in earnings.

**6. Investment Recommendation**

Given the conflicting signals from technical indicators and the potential for short-term correction, investors should consider a cautious approach to investing in MRK. While the company's recent earnings performance is positive, it is essential to monitor future earnings reports and overall market conditions before making any significant investment decisions.